Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy

Stephen J. Sontag, David G. Kogut, Roy Fleischmann, Donald R. Campbell, Joel Richter, Malcolm Robinson, Miles McFarland, Seymour Sabesin, Glen A. Lehman, Donald Castell

Research output: Contribution to journalArticle

36 Scopus citations

Abstract

Purpose: We conducted a randomized, double-blind, multicenter clinical trial to determine whether lansoprazole was superior to continued therapy with histamine H2-receptor antagonist therapy in healing erosive reflux esophagitis. Methods: Investigators from nine medical centers enrolled 159 patients with endoscopically documented esophageal erosions and/or ulcers that had failed to heal with 12 or more wk of at least standard dosages of histamine H2-receptor antagonist therapy. Patients received ranitidine 150 mg b.i.d. for 8 wk or lansoprazole 30 mg for 4 wk followed by either lansoprazole 30 mg or lansoprazole 60 mg for another 4 wk of treatment. Patients underwent endoscopy at screening and at weeks 2, 4, and 8. Results: At 2, 4, and 8 wk of therapy, healing rates were significantly higher in the lansoprazole group compared with the ranitidine group (p < 0.001). By 8 wk, 84% of the lansoprazole group were healed as opposed to only 32% of the ranitidine group. Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0.001) and reducing the need for antacids (p < 0.001). Lansoprazole patients had less interference with sleep and less daytime drowsiness than ranitidine patients (p = 0.05). The percentages of patients with adverse events were similar in both groups. Fasting serum gastrin levels at weeks 4 and 8 were significantly higher in the lansoprazole group compared with the ranitidine group. Conclusion: Eight weeks of lansoprazole therapy is safe, superior to continued ranitidine therapy, and effective in healing more than 80% of patients with erosive reflux esophagitis previously resistant to histamine H2-receptor antagonist therapy.

Original languageEnglish (US)
Pages (from-to)429-437
Number of pages9
JournalAmerican Journal of Gastroenterology
Volume92
Issue number3
StatePublished - Mar 1 1997
Externally publishedYes

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy'. Together they form a unique fingerprint.

  • Cite this

    Sontag, S. J., Kogut, D. G., Fleischmann, R., Campbell, D. R., Richter, J., Robinson, M., McFarland, M., Sabesin, S., Lehman, G. A., & Castell, D. (1997). Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. American Journal of Gastroenterology, 92(3), 429-437.